There’s more to
gout than
hyperuricemia

Gout is a chronic disease with a multifactorial pathogenesis^1-4

Uric acid, renal function, and inflammation are often interconnected in gout

Acute gout flares may increase in frequency and duration and lead to the development of chronic gout¹
Decreased kidney function is strongly associated with hyperuricemia²

Heyperglycemia and renal insufficiency leading to inflammation

In 90% of gout patients, hyperuricemia is related to inadequate renal excretion of uric acid³
Neutrophil-mediated inflammation may be a common link between chronic kidney diseases and gout⁴

Click here to watch a video about the burden and pathogenesis of gout

Look beyond hyperuricemia in the management of gout

In chronic gout, inflammation can be a debilitating and consistent presence³

Immune-mediated inflammation drives gout pathology and symptoms

A key pathologic basis of gout symptoms is neutrophil influx into the joint fluid, which causes a release of inflammatory mediators⁵
Emerging data are showing that chronic inflammation may be present even in asymptomatic gout patients⁶

Chronic inflammation can have a devastating impact if left unaddressed

Persistent inflammation in gout can lead to chronic synovitis, bony erosion, cartilage damage, and tophi formation³

Inflammation can still persist—even when serum uric acid drops below normal baseline levels⁷

Explore why GLOPERBA may be right for your patients

Find out about the important role of colchicine in prophylaxis

Important Safety Information for GLOPERBA^® (colchicine)

Colchicine 0.6 mg oral solution is contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given GLOPERBA.
Fatal overdoses have been reported with colchicine in adults and children. Keep GLOPERBA out of the reach of children.
Blood dyscrasias, such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia, have been reported with colchicine used in therapeutic doses.
Monitor for toxicity and, if present, consider lowering the dose, temporary interruption, or discontinuation of colchicine.
Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider lowering the dose, temporary interruption, or discontinuation of GLOPERBA.
The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

GLOPERBA 0.6 mg oral solution is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied.

GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report suspected adverse reactions, visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information for GLOPERBA.

References: 1. Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76(6):801-808. 2. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358-371. 3. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective—a review. J Adv Res. 2017;8(5):495-511. 4. Finn WF. Kidney disease and gout: the role of the innate immune system. Open Urol Nephrol J. 2016;9(suppl 1):12-21. 5. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8(1):S3. 6. Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155-165. 7. Bădulescu M, Macovei L, Rezuş E. Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):942-945.

There’s more togout thanhyperuricemia

Gout is a chronic disease with a multifactorial pathogenesis1-4